Country: Portugal
Language: English
Source: HMA (Heads of Medicines Agencies)
canine adenovirus 3.5 GKID50, canine distemper virus 3 GKID50, canine parainfluenza virus 3 GKID50, canine parvovirus 4.5 GKID50
Pfizer Limited
QI07AD04
Suspension for injection
canine distemper virus + canine adenovirus + canine parvovirus + canine parainfluenza virus
Dogs Non Food
2012-10-24
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Versican DHPPi, lyophilisate and solvent for suspension for injection for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Composition per 1 ml dose: ACTIVE SUBSTANCES: Freeze-dried fraction (live attenuated)_ _ Minimum Maximum_ _ Canine Distemper virus, strain CDVU 39 10 3.0 TCID 50 * 10 4,7 TCID 50 Canine Adenovirus Type 2, strain CAV2-Bio 13 10 3.5 TCID 50 * 10 4,9 TCID 50 Canine Parvovirus, strain CPV-Bio 12 10 4.5 TCID 50 * 10 6.1 TCID 50 Canine Parainfluenza Type 2 virus, strain CPiV-2-Bio 15 10 3.0 TCID 50 * 10 4.6 TCID 50 * Tissue culture infectious dose-50% Solvent: Water for injection: 1 ml EXCIPIENT: For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Lyophilisate and solvent, for suspension for injection. The visual appearance is as follows: Lyophilisate: Lyophilised vaccine is spongy matter, white to cream colour. Solvent: Clear liquid Reconstituted vaccine: Pink/red, or yellowish colour with light opalescence 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Active immunization of dogs to prevent mortality and clinical signs caused by canine distemper virus , to prevent mortality and clinical signs and reduce viral excretion caused by canine parvovirus, to prevent mortality and clinical signs caused by canine adenovirus type 1 to prevent clinical signs and reduce infection caused by canine ade Read the complete document
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Versican DHPPi, lyophilisate and solvent for suspension for injection for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Composition per 1 ml dose: ACTIVE SUBSTANCES: Freeze-dried fraction (live attenuated)_ _ Minimum Maximum_ _ Canine Distemper virus, strain CDVU 39 10 3.0 TCID 50 * 10 4,7 TCID 50 Canine Adenovirus Type 2, strain CAV2-Bio 13 10 3.5 TCID 50 * 10 4,9 TCID 50 Canine Parvovirus, strain CPV-Bio 12 10 4.5 TCID 50 * 10 6.1 TCID 50 Canine Parainfluenza Type 2 virus, strain CPiV-2-Bio 15 10 3.0 TCID 50 * 10 4.6 TCID 50 * Tissue culture infectious dose-50% Solvent: Water for injection: 1 ml EXCIPIENT: For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Lyophilisate and solvent, for suspension for injection. The visual appearance is as follows: Lyophilisate: Lyophilised vaccine is spongy matter, white to cream colour. Solvent: Clear liquid Reconstituted vaccine: Pink/red, or yellowish colour with light opalescence 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Active immunization of dogs to prevent mortality and clinical signs caused by canine distemper virus , to prevent mortality and clinical signs and reduce viral excretion caused by canine parvovirus, to prevent mortality and clinical signs caused by canine adenovirus type 1 to prevent clinical signs and reduce infection caused by canine ade Read the complete document